Nutritional supplement reduces need for traditional ulcerative colitis treatment

(I-Newswire) April 10, 2005 - "Our study proves that an oral supplement which combines fish oil, soluble fiber and antioxidants is safer and causes fewer side effects than many of the medications currently available to treat ulcerative colitis," said Douglas Seidner, MD, lead study author with The Cleveland Clinic. "This supplement will provide yet another treatment option to alleviate symptoms for patients suffering from this debilitating disease."

Researchers at The Cleveland Clinic conducted a randomized controlled clinical trial of patients 18 and older with mild to moderate active ulcerative colitis to assess the benefits of adding this oral supplement to standard medical therapy for the disease. This study shows that patients on corticosteroid therapy who were given the oral supplement vs. a placebo had a significant reduction in the dose of corticosteroids needed to control clinical symptoms of ulcerative colitis.

Ulcerative colitis is an inflammatory bowel disease in which the lining of the large intestine becomes inflamed and ulcerated, and most commonly affects people between 15 and 40 years of age. Ulcerative colitis can be attributed to an immune disorder or heredity, among other things, and is characterized by abdominal cramps, bloody diarrhea and fever.

Treatments for the disease, including corticosteroids and mesalamine are intended to control inflammation. While corticosteroids are highly effective in the treatment of ulcerative colitis, prolonged use often leads to insomnia, mood alterations, increased appetite, hypertension, osteoporosis and other adverse events.

Adverse effects of corticosteroid use are a concern to physicians and lead to discontinuation of the therapy by many patients. However, more than 25 percent of patients who discontinue the therapy have a relapse of symptoms. Previous smaller studies have shown that fish oil is effective in reducing the need for corticosteroids in ulcerative colitis patients. The current study combines fish oil with soluble fiber to diminish the inflammation associated with ulcerative colitis symptoms and positively affect nutrition.

"The need to find new treatments that are safe, effective and inexpensive remains and physicians should consider adding this combination of active ingredients as an adjuvant therapy for ulcerative colitis," said Seidner.

More information about ulcerative colitis is available at http://www.gastro.org.

About the Study

Researchers at The Cleveland Clinic conducted a randomized controlled study on adult patients over the age of 18 who had ulcerative colitis for at least six months, had active inflammation according to endoscopic exam results and had symptoms of mild to moderate activity of the disease. During the study, patients were either given a ready-to-feed carbohydrate-based drink as a placebo or the Ulcerative Colitis Nutritional Supplement (UCNS) which contains fish oil, soluble fiber and a combination of vitamins and antioxidants. The UCNS was found to reduce reliance on traditional corticosteroid therapy for ulcerative colitis in the study population. The oral supplement is manufactured by Ross Products and Abbott Laboratories and is currently being evaluated for commercial introduction.

About the AGA

The American Gastroenterological Association (AGA) is dedicated to the mission of advancing the science and practice of gastroenterology. Founded in 1897, the AGA is the oldest medical-specialty society in the United States. The AGA's 14,000 members include physicians and scientists who research, diagnose and treat disorders of the gastrointestinal tract and liver. On a monthly basis, the AGA publishes two highly respected journals, Gastroenterology and Clinical Gastroenterology and Hepatology. The AGA's annual meeting is Digestive Disease Week, which is held each May and is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

About Clinical Gastroenterology and Hepatology

The mission of Clinical Gastroenterology and Hepatology is to provide readers with a broad spectrum of themes in clinical gastroenterology and hepatology. This monthly peer-reviewed journal includes original articles as well as scholarly reviews, with the goal that all articles published will be immediately relevant to the practice of gastroenterology and hepatology. For more information, visit www.cghjournal.org.

Contact: Kimberly Wise
media@gastro.org
301-941-2620
American Gastroenterological Association
http://www.gastro.org

Company Contact Information